The cognitive trajectories in normal aging may be affected by medial temporal atrophy (MTA) and amyloid burden, as well as vascular pathologies such as cortical microbleeds (CMB) and white matter hyperintensities (WMH).
Objective:
We addressed here the role of imaging markers in their prediction in a real-world situation.
Methods:
We performed a 4.5-year longitudinal study in 90 older community-dwellers coupling two neuropsychological assessments, MTA estimated with the Schelten’s scale, number of CMB, and WMH evaluated with the Fazekas score at inclusion and follow-up, visual rating of amyloid PET and glucose hypometabolism at follow-up, and APOE genotyping. Regression models were built to explore the association between the continuous cognitive score (CCS) and imaging parameters.
Results:
The number of strictly lobar CMB at baseline (4 or more) was related to a 5.5-fold increase of the risk of cognitive decrement. This association persisted in multivariable models explaining 10.6% of the CCS decrease variance. MTA, and Fazekas score at baseline and amyloid positivity or abnormal FDG PET, were not related to the cognitive outcome. The increase of right MTA at follow-up was the only correlate of CCS decrease both in univariate and multivariable models explaining 9.2% of its variance.
Conclusion:
The present data show that the accumulation of more than four CMB is associated with significant cognitive decrement over time in highly educated elderly persons. They also reveal that the progressive deterioration of cognitive performance within the age-adjusted norms is also related to the increase of visually assessed MTA.
AbbottRA, SkirrowC, JokischM, TimmersM, StrefferJ, van NuetenL, KramsM, WinklerA, PundtN, NathanPJ, RockP, CormackFK, WeimarC (2019) Normative data from linear and nonlinear quantile regression in CANTAB: Cognition in mid-to-late life in an epidemiological sample. Alzheimers Dement (Amst)11, 36–44.
HeddenT, GabrieliJD (2004) Insights into the ageing mind: A view from cognitive neuroscience. Nat Rev Neurosci5, 87–96.
4.
HoogendamYY, HofmanA, van der GeestJN, van der LugtA, IkramMA (2014) Patterns of cognitive function in aging: The Rotterdam Study. Eur J Epidemiol29, 133–140.
5.
RabbittP, DiggleP, SmithD, HollandF, Mc InnesL (2001) Identifying and separating the effects of practice and of cognitive ageing during a large longitudinal study of elderly community residents. Neuropsychologia39, 532–543.
6.
SalthouseTA (2010) Selective review of cognitive aging. J Int Neuropsychol Soc16, 754–760.
7.
ZaninottoP, BattyGD, AllerhandM, DearyIJ (2018) Cognitive function trajectories and their determinants in older people: 8 years of follow-up in the English Longitudinal Study of Ageing. J Epidemiol Community Health72, 685–694.
8.
DownerB, ChenNW, RajiM, MarkidesKS (2017) A longitudinal study of cognitive trajectories in Mexican Americans age 75 and older. Int J Geriatr Psychiatry32, 1122–1130.
9.
LinFV, WangX, WuR, RebokGW, ChapmanBP, Alzheimer’s Disease Neuroimaging Initiative (2017) Identification of successful cognitive aging in the Alzheimer’s disease neuroimaging initiative study. J Alzheimers Dis59, 101–111.
10.
MinJW (2018) A longitudinal study of cognitive trajectories and its factors for Koreans aged 60 and over: A latent growth mixture model. Int J Geriatr Psychiatry33, 755–762.
PlassmanBL, WilliamsJWJr., BurkeJR, HolsingerT, BenjaminS (2010) Systematic review: Factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med153, 182–193.
13.
AljondiR, SzoekeC, StewardC, GorelikA, DesmondP (2020) The effect of midlife cardiovascular risk factors on white matter hyperintensity volume and cognition two decades later in normal ageing women. Brain Imaging Behav14, 51–61.
14.
BauerCM, CabralHJ, KillianyRJ (2018) Multimodal discrimination between normal aging, mild cognitive impairment and Alzheimer’s disease and prediction of cognitive decline. Diagnostics (Basel)8, 14.
15.
CavallinL, BrongeL, ZhangY, OksengardAR, WahlundLO, FratiglioniL, AxelssonR (2012) Comparison between visual assessment of MTA and hippocampal volumes in an elderly, non-demented population. Acta Radiol53, 573–579.
16.
DaughertyAM, RazN (2017) Incident risk and progression of cerebral microbleeds in healthy adults: A multi-occasion longitudinal study. Neurobiol Aging59, 22–29.
17.
HirsigerS, KoppelmansV, MerillatS, ErdinC, NarkhedeA, BrickmanAM, JanckeL (2017) Executive functions in healthy older adults are differentially related to macro- and microstructural white matter characteristics of the cerebral lobes. Front Aging Neurosci9, 373.
18.
MeierIB, GuY, GuzamanVA, WiegmanAF, SchupfN, ManlyJJ, LuchsingerJA, ViswanathanA, Martinez-RamirezS, GreenbergSM, MayeuxR, BrickmanAM (2014) Lobar microbleeds are associated with a decline in executive functioning in older adults. Cerebrovasc Dis38, 377–383.
19.
PetersenRC, WisteHJ, WeigandSD, RoccaWA, RobertsRO, MielkeMM, LoweVJ, KnopmanDS, PankratzVS, MachuldaMM, GedaYE, JackCRJr. (2016) Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol73, 85–92.
20.
Ten KateM, BarkhofF, BoccardiM, VisserPJ, JackCRJr., LovbladKO, FrisoniGB, ScheltensP, Geneva Task Force for the Roadmap of Alzheimer’s Biomarkers (2017) Clinical validity of medial temporal atrophy as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging52, 167–182 e161.
21.
VanhoenackerAS, SneyersB, De KeyzerF, HeyeS, DemaerelP (2017) Evaluation and clinical correlation of practical cut-offs for visual rating scales of atrophy: Normal aging versus mild cognitive impairment and Alzheimer’s disease. Acta Neurol Belg117, 661–669.
22.
VisserPJ, VerheyFR, HofmanPA, ScheltensP, JollesJ (2002) Medial temporal lobe atrophy predicts Alzheimer’s disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry72, 491–497.
23.
ArvanitakisZ, FleischmanDA, ArfanakisK, LeurgansSE, BarnesLL, BennettDA (2016) Association of white matter hyperintensities and gray matter volume with cognition in older individuals without cognitive impairment. Brain Struct Funct221, 2135–2146.
24.
De ReuckJL, DeramecourtV, AugerF, DurieuxN, CordonnierC, DevosD, DefebvreL, MoreauC, Capparos-LefebvreD, PasquierF, LeysD, MaurageCA, BordetR (2015) The significance of cortical cerebellar microbleeds and microinfarcts in neurodegenerative and cerebrovascular diseases. A post-mortem 7.0-tesla magnetic resonance study with neuropathological correlates. Cerebrovasc Dis39, 138–143.
25.
DuboisB, EpelbaumS, NyasseF, BakardjianH, GagliardiG, UspenskayaO, HouotM, ListaS, CacciamaniF, PotierMC, BertrandA, LamariF, BenaliH, ManginJF, ColliotO, GenthonR, HabertMO, HampelH, INSIGHT-preAD study group (2018) Cognitive and neuroimaging features and brain beta-amyloidosis in individuals at risk of Alzheimer’s disease (INSIGHT-preAD): A longitudinal observational study. Lancet Neurol17, 335–346.
26.
KnopmanDS, LundtES, TherneauTM, VemuriP, LoweVJ, KantarciK, GunterJL, SenjemML, MielkeMM, MachuldaMM, RobertsRO, BoeveBF, JonesDT, PetersenRC, JackCRJr. (2018) Joint associations of beta-amyloidosis and cortical thickness with cognition. Neurobiol Aging65, 121–131.
27.
LiL, WuDH, LiHQ, TanL, XuW, DongQ, TanL, YuJT, Alzheimer’s Disease Neuroimaging Initiative (2020) Association of cerebral microbleeds with cognitive decline: A longitudinal study. J Alzheimers Dis75, 571–579.
28.
SonSJ, LeeKS, LeeY, BaekJH, ChoiSH, NaDL, SeoSW, OhBH, HongCH (2012) Association between white matter hyperintensity severity and cognitive impairment according to the presence of the apolipoprotein E (APOE) epsilon4 allele in the elderly: Retrospective analysis of data from the CREDOS study. J Clin Psychiatry73, 1555–1562.
29.
RabinJS, SchultzAP, HeddenT, ViswanathanA, MarshallGA, KilpatrickE, KleinH, BuckleyRF, YangHS, ProperziM, RaoV, KirnDR, PappKV, RentzDM, JohnsonKA, SperlingRA, ChhatwalJP (2018) Interactive associations of vascular risk and beta-amyloid burden with cognitive decline in clinically normal elderly individuals: Findings from the Harvard aging brain study. JAMA Neurol75, 1124–1131.
30.
Al-JanabiOM, PanugantiP, AbnerEL, BahraniAA, MurphyR, BardachSH, Caban-HoltA, NelsonPT, GoldBT, SmithCD, WilcockDM, JichaGA (2018) Global cerebral atrophy detected by routine imaging: Relationship with age, hippocampal atrophy, and white matter hyperintensities. J Neuroimaging28, 301–306.
31.
Graff-RadfordJ, LesnickT, RabinsteinAA, GunterJ, AakreJ, PrzybelskiSA, SpychallaAJ, HustonJ3rd, BrownRDJr., MielkeMM, LoweVJ, KnopmanDS, PetersenRC, JackCRJr., VemuriP, KremersW, KantarciK (2020) Cerebral microbleed incidence, relationship to amyloid burden: The Mayo Clinic Study of Aging. Neurology94, e190–e199.
32.
LimEY, RyuSY, ShimYS, YangDW, ChoAH (2020) Coexistence of cerebral microbleeds and amyloid pathology in patients with cognitive complaints. J Clin Neurol16, 83–89.
33.
ParkJH, SeoSW, KimC, KimGH, NohHJ, KimST, KwakKC, YoonU, LeeJM, LeeJW, ShinJS, KimCH, NohY, ChoH, KimHJ, YoonCW, OhSJ, KimJS, ChoeYS, LeeKH, LeeJH, EwersM, WeinerMW, WerringDJ, NaDL (2013) Pathogenesis of cerebral microbleeds: In vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. Ann Neurol73, 584–593.
34.
RoseboroughA, RamirezJ, BlackSE, EdwardsJD (2017) Associations between amyloid beta and white matter hyperintensities: A systematic review. Alzheimers Dement13, 1154–1167.
35.
ScottJA, BraskieMN, TosunD, MaillardP, ThompsonPM, WeinerM, DeCarliC, CarmichaelOT, ADNI (2016) Cerebral amyloid is associated with greater white-matter hyperintensity accrual in cognitively normal older adults. Neurobiol Aging48, 48–52.
36.
VinkeEJ, de GrootM, VenkatraghavanV, KleinS, NiessenWJ, IkramMA, VernooijMW (2018) Trajectories of imaging markers in brain aging: The Rotterdam Study. Neurobiol Aging71, 32–40.
37.
MontandonML, HerrmannFR, GaribottoV, RodriguezC, HallerS, GiannakopoulosP (2020) Determinants of mesial temporal lobe volume loss in older individuals with preserved cognition: A longitudinal PET amyloid study. Neurobiol Aging87, 108–114.
38.
GiannakopoulosP, RodriguezC, MontandonML, GaribottoV, HallerS, HerrmannFR (2020) Less agreeable, better preserved? A PET amyloid and MRI study in a community-based cohort. Neurobiol Aging89, 24–31.
39.
van der ThielM, RodriguezC, GiannakopoulosP, BurkeMX, LebelRM, GninenkoN, Van De VilleD, HallerS (2018) Brain perfusion measurements using multidelay arterial spin-labeling are systematically biased by the number of delays. AJNR Am J Neuroradiol39, 1432–1438.
40.
XekardakiA, RodriguezC, MontandonML, TomaS, TombeurE, HerrmannFR, ZekryD, LovbladKO, BarkhofF, GiannakopoulosP, HallerS (2015) Arterial spin labeling may contribute to the prediction of cognitive deterioration in healthy elderly individuals. Radiology274, 490–499.
41.
ZanchiD, MontandonML, SinanajI, RodriguezC, DepoorterA, HerrmannFR, BorgwardtS, GiannakopoulosP, HallerS (2017) Decreased fronto-parietal and increased default mode network activation is associated with subtle cognitive deficits in elderly controls. Neurosignals25, 127–138.
42.
HughesCP, BergL, DanzigerWL, CobenLA, MartinRL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry140, 566–572.
43.
PetersenRC, LopezO, ArmstrongMJ, GetchiusTSD, GanguliM, GlossD, GronsethGS, MarsonD, PringsheimT, DayGS, SagerM, StevensJ, Rae-GrantA (2018) Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology90, 126–135.
44.
HerrmannFR, RodriguezC, HallerS, GaribottoV, MontandonML, GiannakopoulosP (2019) Gray matter densities in limbic areas and APOE4 independently predict cognitive decline in normal brain aging. Front Aging Neurosci11, 157.
45.
VarroneA, AsenbaumS, Vander BorghtT, BooijJ, NobiliF, NagrenK, DarcourtJ, KapucuOL, TatschK, BartensteinP, Van LaereK, European Association of Nuclear Medicine Neuroimaging Committee (2009) EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging36, 2103–2110.
46.
ScheltensP, LaunerLJ, BarkhofF, WeinsteinHC, van GoolWA (1995) Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability. J Neurol242, 557–560.
47.
FazekasF, ChawlukJB, AlaviA, HurtigHI, ZimmermanRA (1987) MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol149, 351–356.
BuckleyCJ, SherwinPF, SmithAP, WolberJ, WeickSM, BrooksDJ (2017) Validation of an electronic image reader training programme for interpretation of [18F]flutemetamol beta-amyloid PET brain images. Nucl Med Commun38, 234–241.
DesikanRS, SegonneF, FischlB, QuinnBT, DickersonBC, BlackerD, BucknerRL, DaleAM, MaguireRP, HymanBT, AlbertMS, KillianyRJ (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage31, 968–980.
52.
GaribottoV, MontandonML, ViaudCT, AllaouaM, AssalF, BurkhardPR, RatibO, ZaidiH (2013) Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia. Clin Nucl Med38, e112–117.
53.
HarrellFEJr., LeeKL, CaliffRM, PryorDB, RosatiRA (1984) Regression modelling strategies for improved prognostic prediction. Stat Med3, 143–152.
54.
FarrellME, ChenX, RundleMM, ChanMY, WigGS, ParkDC (2018) Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults. Neurology91, e1809–1821.
55.
GreenbergSM, VernooijMW, CordonnierC, ViswanathanA, Al-Shahi SalmanR, WarachS, LaunerLJ, Van BuchemMA, BretelerMM, Microbleed Study Group (2009) Cerebral microbleeds: A guide to detection and interpretation. Lancet Neurol8, 165–174.
56.
VernooijMW, van der LugtA, IkramMA, WielopolskiPA, NiessenWJ, HofmanA, KrestinGP, BretelerMM (2008) Prevalence and risk factors of cerebral microbleeds: The Rotterdam Scan Study. Neurology70, 1208–1214.
57.
LeiC, LinS, TaoW, HaoZ, LiuM, WuB (2013) Association between cerebral microbleeds and cognitive function: A systematic review. J Neurol Neurosurg Psychiatry84, 693–697.
58.
SepehryAA, RauscherA, HsiungGY, LangDJ (2016) Microbleeds in Alzheimer’s disease: A neuropsychological overview and meta-analysis. Can J Neurol Sci43, 753–759.
59.
BenedictusMR, van HartenAC, LeeuwisAE, KoeneT, ScheltensP, BarkhofF, PrinsND, van der FlierWM (2015) White matter hyperintensities relate to clinical progression in subjective cognitive decline. Stroke46, 2661–2664.
60.
StaekenborgSS, KoedamEL, HennemanWJ, StokmanP, BarkhofF, ScheltensP, van der FlierWM (2009) Progression of mild cognitive impairment to dementia: Contribution of cerebrovascular disease compared with medial temporal lobe atrophy. Stroke40, 1269–1274.
61.
MiwaK, TanakaM, OkazakiS, YagitaY, SakaguchiM, MochizukiH, KitagawaK (2014) Multiple or mixed cerebral microbleeds and dementia in patients with vascular risk factors. Neurology83, 646–653.
62.
van UdenIW, van der HolstHM, TuladharAM, van NordenAG, de LaatKF, Rutten-JacobsLC, NorrisDG, ClaassenJA, van DijkEJ, KesselsRP, de LeeuwFE (2016) White matter and hippocampal volume predict the risk of dementia in patients with cerebral small vessel disease: The RUN DMC study. J Alzheimers Dis49, 863–873.
63.
AkoudadS, WoltersFJ, ViswanathanA, de BruijnRF, van der LugtA, HofmanA, KoudstaalPJ, IkramMA, VernooijMW (2016) Association of cerebral microbleeds with cognitive decline and dementia. JAMA Neurol73, 934–943.
64.
RomeroJR, PreisSR, BeiserA, HimaliJJ, ShoamaneshA, WolfPA, KaseCS, VasanRS, DeCarliC, SeshadriS (2017) Cerebral microbleeds as predictors of mortality: The Framingham Heart study. Stroke48, 781–783.
65.
DingJ, SigurethssonS, JonssonPV, EiriksdottirG, MeirellesO, KjartanssonO, LopezOL, van BuchemMA, GudnasonV, LaunerLJ (2017) Space and location of cerebral microbleeds, cognitive decline, and dementia in the community. Neurology88, 2089–2097.
66.
BosD, WoltersFJ, DarweeshSKL, VernooijMW, de WolfF, IkramMA, HofmanA (2018) Cerebral small vessel disease and the risk of dementia: A systematic review and meta-analysis of population-based evidence. Alzheimers Dement14, 1482–1492.
DebetteS, SchillingS, DuperronMG, LarssonSC, MarkusHS (2019) Clinical significance of magnetic resonance imaging markers of vascular brain injury: A systematic review and meta-analysis. JAMA Neurol76, 81–94.
69.
DeCarliC, FrisoniGB, ClarkCM, HarveyD, GrundmanM, PetersenRC, ThalLJ, JinS, JackCRJr., ScheltensP, Alzheimer’s Disease Cooperative Study Group (2007) Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol64, 108–115.
70.
LiuY, MattilaJ, RuizMA, PaajanenT, KoikkalainenJ, van GilsM, HerukkaSK, WaldemarG, LotjonenJ, SoininenH, Alzheimer’s Disease Neuroimaging Initiative (2013) Predicting AD conversion: Comparison between prodromal AD guidelines and computer assisted PredictAD tool. PLoS One8, e55246.
71.
GlodzikL, de SantiS, TsuiWH, MosconiL, ZinkowskiR, PirragliaE, WangHY, LiY, RichKE, ZetterbergH, BlennowK, MehtaP, de LeonMJ (2011) Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiol Aging32, 2131–2141.
72.
PettigrewC, SoldanA, SloaneK, CaiQ, WangJ, WangMC, MoghekarA, MillerMI, AlbertM, BIOCARD Research Team (2017) Progressive medial temporal lobe atrophy during preclinical Alzheimer’s disease. Neuroimage Clin16, 439–446.
73.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCRJr., KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
74.
AlbertM, ZhuY, MoghekarA, MoriS, MillerMI, SoldanA, PettigrewC, SelnesO, LiS, WangMC (2018) Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years. Brain141, 877–887.
75.
PontecorvoMJ, DevousMDSr., NavitskyM, LuM, SallowayS, SchaerfFW, JenningsD, AroraAK, McGeehanA, LimNC, XiongH, JoshiAD, SiderowfA, MintunMA, 18F-AV-1451-A05 investigators (2017) Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain140, 748–763.
76.
CavedoE, PievaniM, BoccardiM, GalluzziS, BocchettaM, BonettiM, ThompsonPM, FrisoniGB (2014) Medial temporal atrophy in early and late-onset Alzheimer’s disease. Neurobiol Aging35, 2004–2012.
77.
FrisoniGB, PievaniM, TestaC, SabattoliF, BrescianiL, BonettiM, BeltramelloA, HayashiKM, TogaAW, ThompsonPM (2007) The topography of grey matter involvement in early and late onset Alzheimer’s disease. Brain130, 720–730.
78.
ShenQ, LoewensteinDA, PotterE, ZhaoW, AppelJ, GreigMT, RajA, AcevedoA, SchofieldE, BarkerW, WuY, PotterH, DuaraR (2011) Volumetric and visual rating of magnetic resonance imaging scans in the diagnosis of amnestic mild cognitive impairment and Alzheimer’s disease. Alzheimers Dement7, e101–108.
79.
KloppenborgRP, NederkoornPJ, GeerlingsMI, van den BergE (2014) Presence and progression of white matter hyperintensities and cognition: A meta-analysis. Neurology82, 2127–2138.
80.
PrinsND, ScheltensP (2015) White matter hyperintensities, cognitive impairment and dementia: An update. Nat Rev Neurol11, 157–165.
81.
VerdelhoA, MadureiraS, MoleiroC, FerroJM, SantosCO, ErkinjunttiT, PantoniL, FazekasF, VisserM, WaldemarG, WallinA, HennericiM, InzitariD, LADIS Study (2010) White matter changes and diabetes predict cognitive decline in the elderly: The LADIS study. Neurology75, 160–167.
LauriolaM, EspositoR, Delli PizziS, de ZambottiM, LondrilloF, KramerJH, RabinoviciGD, TartaroA (2017) Sleep changes without medial temporal lobe or brain cortical changes in community-dwelling individuals with subjective cognitive decline. Alzheimers Dement13, 783–791.
85.
PerrotinA, La JoieR, de La SayetteV, BarreL, MezengeF, MutluJ, GuilloteauD, EgretS, EustacheF, ChetelatG (2017) Subjective cognitive decline in cognitively normal elders from the community or from a memory clinic: Differential affective and imaging correlates. Alzheimers Dement13, 550–560.
